Kidney Week 2020 Reimagined: Exhibitor Spotlight Schedule
On-Demand October 22 - December 4, 2020
Hear from leading experts on the latest advances in nephrology practices, therapies, services, and technologies. Available through December 4, click the Exhibits and Spotlights Tab on the Kidney Week 2020 Reimagined homepage to access these presentations at your convenience.
A Novel Approach to Anemia - Introducing HIF SoPHIstication
Supported by Akebia Therapeutics, Inc.
Oxalate and the Kidneys: Primary Hyperoxaluria in Practice
Supported by Alnylam Pharmaceuticals
Shortening the Journey to Fabry Disease Diagnosis - Perspectives from a Patient and Nephrologist
Supported by Amicus Therapeutics
Advancing the Science of Phosphate Absorption: Paracellular Pathway and Implications for Phosphorus Management
Supported by Ardelyx
The Efficacy and Safety of LOKELMA® (sodium zirconium cyclosilicate)
Supported by AstraZeneca
Anemia of CKD: A Changing Perspective Based on the HIF Pathway
Supported by AstraZeneca
Lupus Nephritis: The Importance of Active Surveillance, Early Diagnoses, and Successful Treatment
Supported by Aurinia Pharmaceuticals
Where There's Smoke, There's Fire: Uncovering the Role of Inflammation and Fibrosis in CKD Progression in T2D
Supported by Bayer
Understanding the Interconnectivity of the CV, Renal, and Metabolic Systems
Supported by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA
AlloSure as a Tool for Surveillance of Renal Transplant Patients: Real World Evidence and Clinical Utility
Supported by CareDx
Rethinking Fabry Disease: Reasons to Look into the Future
Supported by Chiesi Global Rare Diseases
Lupus Nephritis: The CASE for Early Recognition and Management
Supported by GSK
Discover the Genetic Etiology of Kidney Disease with Renasight
Supported by Natera
IgA Nephropathy - Understanding the Role of the Complement Pathway
Supported by Novartis
IgA Nephropathy: Pathophysiology, Therapeutic Advances, and Ongoing Clinical Trials
Supported by Omeros Corporation
Taking the Next Step in the Management of ADPKD: Insights from a Multidisciplinary Panel
Supported by Otsuka America Pharmaceutical, Inc.
Understanding Innovative Endpoints in Glomerular Diseases
Supported by Retrophin
Minimize Risk of Iron Overload: Centralize Delivery With a Novel Approach to Anemia Management in Hemodialysis
Supported by Rockwell Medical
Evolving Concepts in ADPKD
Supported by Sanofi Genzyme
Renal Phosphate Wasting Disorders: X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO)
Supported by Ultragenyx Pharmaceutical Inc.
The Exhibitor Spotlights are not Continuing Education (CE) activities.
*Additional information included by clicking on title if provided by supporter.
